Suresh S. Ramalingam
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta
USA
Name/email consistency: high
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Ramalingam, S.S., Blackhall, F., Krzakowski, M., Barrios, C.H., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D.C., Frank, R., Letrent, S.P., Ruiz-Garcia, A., Taylor, I., Liang, J.Q., Campbell, A.K., O'Connell, J., Boyer, M. J. Clin. Oncol. (2012)
- Hypogonadism related to crizotinib therapy: Implications for patient care. Ramalingam, S.S., Shaw, A.T. Cancer (2012)
- Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). Ramalingam, S.S., Davies, A.M., Longmate, J., Edelman, M.J., Lara, P.N., Vokes, E.E., Villalona-Calero, M., Gitlitz, B., Reckamp, K., Salgia, R., Wright, J.J., Belani, C.P., Gandara, D.R. J. Thorac. Oncol (2011)
- Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer. Ramalingam, S.S., Spigel, D.R., Chen, D., Steins, M.B., Engelman, J.A., Schneider, C.P., Novello, S., Eberhardt, W.E., Crino, L., Habben, K., Liu, L., Jänne, P.A., Brownstein, C.M., Reck, M. J. Clin. Oncol. (2011)
- Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504). Ramalingam, S.S., Lee, J.W., Belani, C.P., Aisner, S.C., Kolesar, J., Howe, C., Velasco, M.R., Schiller, J.H. J. Clin. Oncol. (2011)
- Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Ramalingam, S.S., Belani, C.P., Mack, P.C., Vokes, E.E., Longmate, J., Govindan, R., Koczywas, M., Ivy, S.P., Gandara, D.R. J. Thorac. Oncol (2010)
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. Ramalingam, S.S., Maitland, M.L., Frankel, P., Argiris, A.E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E.E., Gandara, D.R., Belani, C.P. J. Clin. Oncol. (2010)
- Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Ramalingam, S.S., Kummar, S., Sarantopoulos, J., Shibata, S., LoRusso, P., Yerk, M., Holleran, J., Lin, Y., Beumer, J.H., Harvey, R.D., Ivy, S.P., Belani, C.P., Egorin, M.J. J. Clin. Oncol. (2010)
- Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. Ramalingam, S.S., Belani, C.P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., Gandara, D. J. Thorac. Oncol (2009)
- The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Ramalingam, S.S., Khuri, F.R. Oncologist (2009)
- Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. Ramalingam, S.S., Dahlberg, S.E., Langer, C.J., Gray, R., Belani, C.P., Brahmer, J.R., Sandler, A.B., Schiller, J.H., Johnson, D.H. J. Clin. Oncol. (2008)
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Ramalingam, S.S., Egorin, M.J., Ramanathan, R.K., Remick, S.C., Sikorski, R.P., Lagattuta, T.F., Chatta, G.S., Friedland, D.M., Stoller, R.G., Potter, D.M., Ivy, S.P., Belani, C.P. Clin. Cancer Res. (2008)
